Men With Castrate Resistant Prostate Cancer Can Experience A PSA Flare When Starting Docetaxel Chemotherapy

The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts of 56 men who received docetaxel-based chemotherapy in three different centers from August 1999 to August 2007. They found that [...]

The Impact of Co-morbidity on Outcomes in Men with Advanced Prostate Cancer Treated with Chemotherapy (Docetaxel)

Side effects, or what are known as co-morbidities, often discourage men who have metastatic prostate cancer from continuing with chemotherapy (docetaxel). The question often asked is there a relationship between having side effects and the ultimate efficacy of the chemotherapy? In other words does having side effects have an effect on overall survival? To answer [...]

Our New Therapies and the Development of Cross Resistance to these Drugs

Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]

Make Sure You Receive the Correct IV Treatment, Injection and Dosage

It is vital that you take an active role in making sure that you are going to receive the correct IV treatment and injections. Mistakes do happen, protect yourself. Make sure that you personally double check to confirm you're receiving the correct treatment. Don't sit back and rely on another person, errors do occur and [...]

Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer *

Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]

Liver Metastases and ECF – A Possible Treatment In A Not Good Situation

Liver metastases are uncommon in men with castrate resistant prostate cancer (CRPC). Having liver metastases is associated with more serious disease and shorter survival. How to treat men with liver metastases is still not very clear. It is felt that more active treatment might benefit these men. A standard regimen for treating gastric cancer is [...]

Europe Awaits Xtandi – A Positive CHMP Opinion on the Clearance of Enzalutamide In the Pre-Chemotherapy Stage of Prostate Cancer

Some good news for my European brothers, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adapted a positive opinion in support of the label expansion of enzalutamide (XTANDI) to include the treatment of men with metastatic castrate resistant prostate cancer (MCRPC) who are asymptomatic or mildly symptomatic after the failure [...]

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

Phase 4 PROCEED Trial Shows Earlier Provenge Delays First Chemotherapy Exposure

Provenge or Sipuleucel-T (sip-T) remains not well understood by many prostate cancer survivors as well as some treating physicians. Because Provenge does not immediately control PSA or disease progression it creates a situation where some individuals are skeptical as to its efficacy. This is true despite the clear survival advantage demonstrated in clinical trials. This [...]

Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment

Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that it is for the treatment of men with metastatic castration-resistant prostate cancer. This label is basically the same as for [...]

Go to Top